Moderna says it can start analyzing how well its COVID-19 vaccine works
Share Now on:
Marketplace’s Nancy Marshall-Genzer has the news. The following is an edited transcript of her conversation with “Marketplace Morning Report” host David Brancaccio.
Nancy Marshall-Genzer: You have to have a certain number of infections before you can determine if a vaccine is effective. In Moderna’s vaccine trial, half of the 30,000 participants got the vaccine. The other half got a placebo. Moderna says around 50 of the volunteers have now gotten COVID-19. So, now it will analyze how many of them received the vaccine versus the placebo.
David Brancaccio: And what kind of vaccine is this one?
Marshall-Genzer: It’s the same type Pfizer is making. They’re not like a typical vaccine, which involves injecting inactivated virus into a patient. The Pfizer and Moderna vaccines use messenger RNA. The vaccine prompts the body to produce COVID-19’s spike protein. A person’s immune system then learns to attack and destroy it.
Brancaccio: OK, so apparent progress, but distribution is a big hurdle.
Marshall-Genzer: That could be a challenge, at least in developing countries. These vaccines need to be kept very cold, below freezing. That’s not such a problem in the U.S., but could be difficult in other nations. Moderna has already agreed to supply 100 million doses to the U.S.
There’s a lot happening in the world. Through it all, Marketplace is here for you.
You rely on Marketplace to break down the world’s events and tell you how it affects you in a fact-based, approachable way. We rely on your financial support to keep making that possible.
Your donation today powers the independent journalism that you rely on. For just $5/month, you can help sustain Marketplace so we can keep reporting on the things that matter to you.